Daratumumab for autoimmune diseases: a systematic review

Marie-Therese Holzer1, Nikolas Ruffer2, Tobias B Huber3

  • 1Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany m.holzer@uke.de.

RMD Open
|December 15, 2023
PubMed
Summary

Daratumumab, a CD38-targeting antibody, shows promise for refractory autoimmune diseases, with 81% of patients experiencing remission or improvement. Further clinical trials are needed to optimize its use and manage side effects.

Related Concept Videos